Updated:
Champalimaud Foundation
The Champalimaud Foundation was created in 2004 through the will of Portuguese entrepreneur António de Sommer Champalimaud. Leonor Beleza has served as...
Champalimaud Foundation
The Champalimaud Foundation was created in 2004 through the will of Portuguese entrepreneur António de Sommer Champalimaud. Leonor Beleza has served as president of the board from inception. The foundation operates as a private non-profit with a mandate limited to advanced biomedical research and clinical care. Capital deployment centers on owned research infrastructure and targeted grants. Asset classes include direct real estate holdings such as the Champalimaud Centre for the Unknown and the Botton-Champalimaud Pancreatic Cancer Centre, plus a financial portfolio of bonds and equities. The foundation has committed to early-stage biotechnology vehicles including Faber Blue Pioneers I and maintains ownership in LiMM Therapeutics. Activity remains concentrated in Portugal with additional partnerships extending to global research networks. The endowment stands at 1.2B under external bank management. The organization employs no disclosed investment professionals and maintains its sole base in Lisbon. Adjacent vehicles include the biennial Champalimaud Vision Award. In October 2024 the foundation hosted the Botton-Champalimaud International Pancreatic Cancer Conference. Governance rests with a board that includes family representation and external directors such as António Horta-Osório. This structure separates philanthropic operations from the original commercial interests while retaining direct control over research facilities and grant allocation.
General information
Firm type
Endowment / Foundation
Year founded
2004
Location
Region
Europe
Country
Portugal
City
Lisbon
Corporate office
Champalimaud Centre for the Unknown Avenida de Brasília
Principals
Leonor Beleza
President of the Board of Directors
António Horta-Osório
Non-executive Director
Sector focus
Frequently asked questions
Who runs investment decisions at Champalimaud Foundation?
Leonor Beleza serves as president of the board. External specialized banks manage the financial portfolio. The board approves major capital allocations to research facilities and grants.
Does Champalimaud Foundation participate in fund commitments or only direct deals?
The foundation holds positions in at least one venture vehicle and maintains direct ownership of research centers and one biotechnology company. External managers handle the listed equity and bond allocation.
Where does the underlying wealth come from?
The endowment originated from the estate of António de Sommer Champalimaud whose businesses spanned banking, insurance, mining and cement.
What investment stages does Champalimaud Foundation typically target?
Activity includes early-stage biotechnology holdings and direct development of research infrastructure. The financial portfolio maintains a 52 percent allocation to low-risk assets.
How is Champalimaud Foundation related to its major donors?
The Botton family funded the pancreatic cancer centre through a 50M euro donation. The Würth family supported a separate research centre. Both operate as co-investors on specific projects.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: